Phrixus to study P-188 NF in Phase II trial to treat DMD
US-based Phrixus Pharmaceuticals is set to conduct a Phase II clinical trial of Poloxamer 188 NF (P-188 NF) for the treatment of non-ambulatory patients with Duchenne muscular dystrophy (DMD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Muscular Dystrophy | Pharmaceuticals | Reflex Sympathetic Dystrophy | Study